Scientific

Event Publication Document
Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
Avidity-Engineered CD3 Engaging DARPin Targeting Three Tumor Associated Antigens Induces Strong and Specific T Cell Dependent Killing of AML Cells with Potential for Improved Safety
Safety, tolerability and pharmacokinetics of ensovibep in patients with mild to moderate COVID-19 - preliminary report of a phase 2a, open-label, single dose escalation study
Ensovibep, a potential antiviral COVID-19 treatment, is safe and well tolerated in healthy volunteers: preliminary safety and PK results from a phase 1, multi-part, ascending, single-dose
EMPATHY: A Ph2 3 Randomized, Placebo Controlled Trial Evaluating Safety and Efficacy of Ensovibep in Ambulatory COVID 19 Patients
CD3-slow release DARPin® (CD3-SRD) concept – a smart solution for reducing cytokine release syndrome while maintaining optimal anti-tumor efficacy
MP0317: MP0317, a CD40xFAP targeting multi-specific DARPin® therapeutic, drives immune activation and reverts myeloid-mediated T-cell suppression in vitro and ex vivo
pMHC: Application of the DARPin® technology for specific targeting of tumor-associated MHC class I:peptide complexes
Prodrug: A solution to T-cell engager toxicity: An anti-CD3 Prodrug DARPin (CD3-PDD) shows no toxicity, but potent anti-tumor activity in a humanized mouse model
AML: Immunomodulatory Agents and Interventions

Investors